PortfoliosLab logoPortfoliosLab logo
GIB vs. NBIX
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

GIB vs. NBIX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in CGI Inc (GIB) and Neurocrine Biosciences, Inc. (NBIX). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, GIB achieves a -20.45% return, which is significantly lower than NBIX's 17.61% return. Over the past 10 years, GIB has underperformed NBIX with an annualized return of 4.25%, while NBIX has yielded a comparatively higher 12.71% annualized return.


GIB

1D
-0.12%
1M
11.73%
6M
-14.41%
YTD
-20.45%
1Y
-23.67%
3Y*
-9.95%
5Y*
-4.08%
10Y*
4.25%
ALL TIME*
9.36%

NBIX

1D
-10.08%
1M
-0.58%
6M
22.59%
YTD
17.61%
1Y
30.08%
3Y*
17.27%
5Y*
12.34%
10Y*
12.71%
ALL TIME*
9.11%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$41.80M$36.08M$33.67M
$278.93M$232.17M$211.02M

GIB vs. NBIX - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
GIB
CGI Inc
-20.45%-15.19%2.07%24.47%-2.68%11.59%-5.26%36.80%12.63%13.12%
NBIX
Neurocrine Biosciences, Inc.
17.61%3.90%3.60%10.31%40.24%-11.14%-10.83%50.53%-7.96%100.49%

Correlation

The correlation between GIB and NBIX is 0.05, meaning there was essentially no consistent relationship between their historical price movements. Each responded to its own set of market drivers.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

0.05

Correlation (3Y)
Balances recent behavior with more history.

0.13

Correlation (5Y)
Shows whether the relationship held over a longer period.

0.17

Correlation (10Y)
Provides a long-term view across more market conditions.

0.24

Correlation (All Time)
Calculated using the full available price history since Oct 7, 1998

0.19

The correlation between GIB and NBIX shifts across timeframes, from 0.05 (1 year) to 0.24 (10 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

GIB:

$15.64B

NBIX:

$16.77B

EPS

GIB:

CA$7.71

NBIX:

$6.84

PE Ratio

GIB:

13.29

NBIX:

24.39

PEG Ratio

GIB:

1.67

NBIX:

0.48

PS Ratio

GIB:

1.36

NBIX:

5.10

PB Ratio

GIB:

2.18

NBIX:

4.35

Total Revenue (TTM)

GIB:

CA$16.35B

NBIX:

$3.37B

Gross Profit (TTM)

GIB:

CA$3.35B

NBIX:

$3.31B

EBITDA (TTM)

GIB:

CA$2.98B

NBIX:

$940.50M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

GIB vs. NBIX — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

GIB
GIB Risk / Return Rank: 1515
Overall Rank
GIB Sharpe Ratio Rank: 1111
Sharpe Ratio Rank
GIB Sortino Ratio Rank: 1414
Sortino Ratio Rank
GIB Omega Ratio Rank: 1212
Omega Ratio Rank
GIB Calmar Ratio Rank: 2020
Calmar Ratio Rank
GIB Martin Ratio Rank: 1717
Martin Ratio Rank

NBIX
NBIX Risk / Return Rank: 7171
Overall Rank
NBIX Sharpe Ratio Rank: 7474
Sharpe Ratio Rank
NBIX Sortino Ratio Rank: 6868
Sortino Ratio Rank
NBIX Omega Ratio Rank: 7070
Omega Ratio Rank
NBIX Calmar Ratio Rank: 7373
Calmar Ratio Rank
NBIX Martin Ratio Rank: 7171
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

GIB vs. NBIX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for CGI Inc (GIB) and Neurocrine Biosciences, Inc. (NBIX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


GIBNBIXDifference
Sharpe ratioReturn per unit of total volatility

-1.68

Sortino ratioReturn per unit of downside risk

-2.27

Omega ratioGain probability vs. loss probability

0.87

1.19

-0.32

Calmar ratioReturn relative to maximum drawdown

-0.65

1.45

-2.09

Martin ratioReturn relative to average drawdown

-1.16

3.18

-4.34

GIB vs. NBIX - Sharpe Ratio Comparison

The current GIB Sharpe Ratio is -0.77, which is lower than the NBIX Sharpe Ratio of 0.91. The chart below compares the historical Sharpe Ratios of GIB and NBIX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

GIB vs. NBIX - Drawdown Comparison

The maximum GIB drawdown since its inception was -86.78%, smaller than the maximum NBIX drawdown of -97.21%. Use the drawdown chart below to compare losses from any high point for GIB and NBIX.


Loading charts...

Drawdown Indicators


GIBNBIXDifference

Max Drawdown

Largest peak-to-trough decline

-86.78%

-97.21%

+10.43%

Max Drawdown (1Y)

Largest decline over 1 year

-36.77%

-20.90%

-15.87%

Max Drawdown (3Y)

Largest decline over 3 years

-49.54%

-42.89%

-6.65%

Max Drawdown (5Y)

Largest decline over 5 years

-49.54%

-42.89%

-6.65%

Max Drawdown (10Y)

Largest decline over 10 years

-49.54%

-46.39%

-3.15%

Current Drawdown

Current decline from peak

-39.76%

-10.08%

-29.68%

Average Drawdown

Average peak-to-trough decline

-32.55%

-43.66%

+11.11%

Ulcer Index

Depth and duration of drawdowns from previous peaks

20.44%

9.47%

+10.97%

Volatility

GIB vs. NBIX - Volatility Comparison

The current volatility for CGI Inc (GIB) is 10.64%, while Neurocrine Biosciences, Inc. (NBIX) has a volatility of 14.12%. This indicates that GIB experiences smaller price fluctuations and is considered to be less risky than NBIX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


GIBNBIXDifference

Volatility (1M)

Calculated over the trailing 1-month period

10.64%

14.12%

-3.48%

Volatility (6M)

Calculated over the trailing 6-month period

26.97%

26.01%

+0.96%

Volatility (1Y)

Calculated over the trailing 1-year period

30.79%

33.74%

-2.95%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

23.49%

33.17%

-9.68%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

22.76%

39.18%

-16.42%

Dividends

GIB vs. NBIX - Dividend Comparison

GIB's dividend yield for the trailing twelve months is around 0.65%, while NBIX has not paid dividends to shareholders.


PositionTTM20252024
GIB
CGI Inc
0.65%0.48%0.10%
NBIX
Neurocrine Biosciences, Inc.
0.00%0.00%0.00%

Financials

GIB vs. NBIX - Financials Comparison

This section allows you to compare key financial metrics between CGI Inc and Neurocrine Biosciences, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

GIB vs. NBIX - Profitability Comparison

The chart below illustrates the profitability comparison between CGI Inc and Neurocrine Biosciences, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

GIB - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, CGI Inc reported a gross profit of 684.28M and revenue of 4.17B. Therefore, the gross margin over that period was 16.4%.

NBIX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Neurocrine Biosciences, Inc. reported a gross profit of 935.80M and revenue of 959.00M. Therefore, the gross margin over that period was 97.6%.

GIB - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, CGI Inc reported an operating income of 684.28M and revenue of 4.17B, resulting in an operating margin of 16.4%.

NBIX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Neurocrine Biosciences, Inc. reported an operating income of 151.50M and revenue of 959.00M, resulting in an operating margin of 15.8%.

GIB - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, CGI Inc reported a net income of 445.87M and revenue of 4.17B, resulting in a net margin of 10.7%.

NBIX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Neurocrine Biosciences, Inc. reported a net income of 144.40M and revenue of 959.00M, resulting in a net margin of 15.1%.


Frequently Asked Questions


GIB and NBIX have a correlation of 0.05, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

NBIX has higher volatility (14.12%) compared to GIB (10.64%). In terms of maximum drawdown, GIB dropped -86.78% vs NBIX's -97.21%.

NBIX currently has the higher Sharpe Ratio (0.91 vs -0.77), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for GIB and NBIX

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer